Acquisition History / Marubeni Corporation / Sumitomo Pharma Asia drug sales business (majority stake)
Marubeni Corporation Acquires Sumitomo Pharma Asia drug sales business (majority stake)
Announced April 3, 2025 — $301M
What happened
Sumitomo Pharma's Asia business sells prescription drugs across Southeast Asia and China. Trading house Marubeni announced it would purchase a majority stake for roughly ¥45B.
- Acquirer
- Marubeni Corporation
- Target
- Sumitomo Pharma Asia drug sales business (majority stake)
- Announced
- April 3, 2025
- Price
- $301M
- Industry
- Pharmaceutical distribution
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Marubeni Corporation acquire Sumitomo Pharma Asia drug sales business (majority stake)?
Marubeni Corporation acquired Sumitomo Pharma Asia drug sales business (majority stake) on April 3, 2025. This was Marubeni Corporation's 1st publicly tracked acquisition out of 1 we have on record.
How much did Marubeni Corporation pay for Sumitomo Pharma Asia drug sales business (majority stake)?
Marubeni Corporation paid $301M for Sumitomo Pharma Asia drug sales business (majority stake).
What does Sumitomo Pharma Asia drug sales business (majority stake) do?
Sumitomo Pharma's Asia business sells prescription drugs across Southeast Asia and China. Trading house Marubeni announced it would purchase a majority stake for roughly ¥45B.
What other Pharmaceutical distribution companies has Marubeni Corporation acquired?
Sumitomo Pharma Asia drug sales business (majority stake) is Marubeni Corporation's only publicly tracked acquisition in Pharmaceutical distribution so far.